Matches in SemOpenAlex for { <https://semopenalex.org/work/W3022626677> ?p ?o ?g. }
Showing items 1 to 75 of
75
with 100 items per page.
- W3022626677 endingPage "S47" @default.
- W3022626677 startingPage "S47" @default.
- W3022626677 abstract "Patients with spinal cord injury (SCI) commonly have comorbid anxiety disorders (Von Korff, Pain, 2005). Pregabalin is approved in the US for treatment of pain associated with diabetic peripheral neuropathy and postherpetic neuralgia, and it has shown rapid, sustained efficacy for treating pain associated with SCI. Pregabalin has also demonstrated significant efficacy for treating generalized anxiety disorder in 5 of 6 RCTs. This analysis was performed to determine whether the presence of clinically meaningful anxiety symptoms at baseline—identified by using the Hospital Anxiety and Depression Scale-Anxiety subscale score (HADS-A)—influenced pregabalin’s efficacy for treating central neuropathic pain associated with SCI. 137 SCI patients were randomized to flexibly-dosed pregabalin (150-600 mg/d) or placebo for 12 weeks. Pain relief was assessed by mean change from baseline to endpoint in pain score (based on an 11-point scale derived from patients’ daily pain diaries). The HADS was administered at baseline and endpoint. For this analysis, patients were stratified into 2 groups: baseline HADS-A≤10(indicating no or mild anxiety symptoms) and baseline HADS-A>10 (indicating moderate to severe anxiety symptoms). Pregabalin-treated patients received a mean daily dosage of 388 mg. Fifty-eight pregabalin and 47 placebo patients had baseline HADS-A≤10, while 11 pregabalin and 20 placebo patients had baseline HADS-A>10. Regardless of HADS-A stratum, patients treated with pregabalin had significantly greater reduction in pain score from baseline to endpoint than did those receiving placebo: HADS-A≤10, −1.69 vs −0.58, P=.001; HADS-A>10, −4.12 vs 0.41, P<.001. Pregabalin was also associated with significant reduction in HADS-A score from baseline to endpoint relative to placebo (−1.72 vs −0.66, P<.05). Pregabalin efficaciously treated pain in patients with and without comorbid anxiety symptoms. Additionally, treatment with pregabalin was associated with a statistically significant decrease in HADS-A subscale score from baseline to endpoint, suggesting improvement of comorbid anxiety." @default.
- W3022626677 created "2020-05-13" @default.
- W3022626677 creator A5012796839 @default.
- W3022626677 creator A5020043337 @default.
- W3022626677 creator A5059723428 @default.
- W3022626677 creator A5070426093 @default.
- W3022626677 date "2006-04-01" @default.
- W3022626677 modified "2023-10-14" @default.
- W3022626677 title "(783)" @default.
- W3022626677 doi "https://doi.org/10.1016/j.jpain.2006.01.185" @default.
- W3022626677 hasPublicationYear "2006" @default.
- W3022626677 type Work @default.
- W3022626677 sameAs 3022626677 @default.
- W3022626677 citedByCount "0" @default.
- W3022626677 crossrefType "journal-article" @default.
- W3022626677 hasAuthorship W3022626677A5012796839 @default.
- W3022626677 hasAuthorship W3022626677A5020043337 @default.
- W3022626677 hasAuthorship W3022626677A5059723428 @default.
- W3022626677 hasAuthorship W3022626677A5070426093 @default.
- W3022626677 hasBestOaLocation W30226266771 @default.
- W3022626677 hasConcept C118552586 @default.
- W3022626677 hasConcept C126322002 @default.
- W3022626677 hasConcept C142724271 @default.
- W3022626677 hasConcept C168563851 @default.
- W3022626677 hasConcept C1862650 @default.
- W3022626677 hasConcept C203092338 @default.
- W3022626677 hasConcept C204787440 @default.
- W3022626677 hasConcept C27081682 @default.
- W3022626677 hasConcept C2776468701 @default.
- W3022626677 hasConcept C2777107010 @default.
- W3022626677 hasConcept C2778739829 @default.
- W3022626677 hasConcept C2778866549 @default.
- W3022626677 hasConcept C2780052408 @default.
- W3022626677 hasConcept C2781118164 @default.
- W3022626677 hasConcept C42219234 @default.
- W3022626677 hasConcept C558461103 @default.
- W3022626677 hasConcept C71924100 @default.
- W3022626677 hasConceptScore W3022626677C118552586 @default.
- W3022626677 hasConceptScore W3022626677C126322002 @default.
- W3022626677 hasConceptScore W3022626677C142724271 @default.
- W3022626677 hasConceptScore W3022626677C168563851 @default.
- W3022626677 hasConceptScore W3022626677C1862650 @default.
- W3022626677 hasConceptScore W3022626677C203092338 @default.
- W3022626677 hasConceptScore W3022626677C204787440 @default.
- W3022626677 hasConceptScore W3022626677C27081682 @default.
- W3022626677 hasConceptScore W3022626677C2776468701 @default.
- W3022626677 hasConceptScore W3022626677C2777107010 @default.
- W3022626677 hasConceptScore W3022626677C2778739829 @default.
- W3022626677 hasConceptScore W3022626677C2778866549 @default.
- W3022626677 hasConceptScore W3022626677C2780052408 @default.
- W3022626677 hasConceptScore W3022626677C2781118164 @default.
- W3022626677 hasConceptScore W3022626677C42219234 @default.
- W3022626677 hasConceptScore W3022626677C558461103 @default.
- W3022626677 hasConceptScore W3022626677C71924100 @default.
- W3022626677 hasIssue "4" @default.
- W3022626677 hasLocation W30226266771 @default.
- W3022626677 hasOpenAccess W3022626677 @default.
- W3022626677 hasPrimaryLocation W30226266771 @default.
- W3022626677 hasRelatedWork W1997961150 @default.
- W3022626677 hasRelatedWork W2031244515 @default.
- W3022626677 hasRelatedWork W2054234757 @default.
- W3022626677 hasRelatedWork W2136439636 @default.
- W3022626677 hasRelatedWork W2141209877 @default.
- W3022626677 hasRelatedWork W2514576596 @default.
- W3022626677 hasRelatedWork W2527720274 @default.
- W3022626677 hasRelatedWork W2944997016 @default.
- W3022626677 hasRelatedWork W3085870493 @default.
- W3022626677 hasRelatedWork W3166379374 @default.
- W3022626677 hasVolume "7" @default.
- W3022626677 isParatext "false" @default.
- W3022626677 isRetracted "false" @default.
- W3022626677 magId "3022626677" @default.
- W3022626677 workType "article" @default.